Use of Generic Antiretroviral Drugs and Single-Tablet Regimen De-Simplification for the Treatment of HIV Infection in Spain.
Por:
Ruiz-Alguero, M, Alejos, B, Yubero, C, Jaume, M, Iribarren, J, Asensi, V, Pasquau, F, Galera, C, Pascual-Carrasco, M, Munoz, A, Jarrin, I and Suarez-Garcia, I
Publicada:
1 jun 2022
Ahead of Print:
2 may 2022
Resumen:
The present study sought to describe the use of generic drugs and single-tablet regimen (STR) de-simplification for the treatment of human immunodeficiency virus (HIV) infection among 41 hospitals from the cohort of the Spanish HIV/AIDS Research Network (CoRIS). In June 2018, we collected information on when generic antiretroviral drugs (ARVs) were introduced in the different hospitals, how the decisions to use them were made, and how the information was provided to the patients. Most of the nine available generic ARVs in Spain by June 2018 had been introduced in at least 85% of the participating hospitals, except for zidovudine (AZT)/lamivudine (3TC) and AZT. The time difference between the effective marketing date of each generic ARV and its first dispensing date in the hospitals was much shorter for the more recently approved generic ARV since the year 2017. However, only up to 20% of the hospitals de-simplified efavirenz (EFV)/tenofovir disoproxil (TDF)/emtricitabine (FTC), dolutegravir (DTG)/abacavir (ABC)/3TC, and rilpivirine (RPV)/TDF/FTC (to generic EFV+TDF/FTC, DTG+generic ABC/3TC, and RPV+generic TDF/FTC, respectively), whereas the generic STR EFV/TDF/FTC was introduced in 87.8% of the centers. The median times between the date of effective marketing of generic TDF/FTC and the date of de-simplification of EFV/TDF/FTC and RPV/TDF/FTC were 723 [interquartile range (IQR): 369-1,119] and 234 (IQR: 142-264) days, respectively; this time was 155 (IQR: 28-287) days for de-simplification of DTG/ABC/3TC. In conclusion, despite the widespread use of generic ARVs, STRs de-simplification was only undertaken in <20% of the hospitals. There was wide variability in the timing of the introduction of each generic ARV after they were available in the market.
Filiaciones:
Ruiz-Alguero, M:
Inst Hlth Carlos, Natl Ctr Epidemiol, Madrid, Spain
Inst Hlth CArlos III, CIBER Enfermedades Infecciosas, Madrid, Spain
Alejos, B:
Inst Hlth Carlos, Natl Ctr Epidemiol, Madrid, Spain
Inst Hlth Carlos II Monforte Lemos, Natl Ctr Epidemiol, Madrid 528029, Spain
Yubero, C:
Hosp Univ Infanta Sofia, Dept Hosp Pharm, Madrid, Spain
Jaume, M:
Hosp Univ Son Espases, Palma De Mallorca, Spain
Iribarren, J:
Hosp Univ Donostia, Serv Enfermedades Infecciosas, Inst Invest BioDonostia, San Sebastian, Spain
Asensi, V:
Hosp Univ Cent Asturias, Oviedo, Spain
:
Hosp Marina Baixa, Villajoyosa, Spain
Galera, C:
Hosp Univ Virgen Arrixaca, El Palmar, Spain
Pascual-Carrasco, M:
Inst Hlth CArlos III, CIBER Enfermedades Infecciosas, Madrid, Spain
Un Invest Telemed & Salud Digital UITes, Inst Salud Carlos III, Madrid, Spain
Munoz, A:
Inst Hlth CArlos III, CIBER Enfermedades Infecciosas, Madrid, Spain
Un Invest Telemed & Salud Digital UITes, Inst Salud Carlos III, Madrid, Spain
Jarrin, I:
Inst Hlth Carlos, Natl Ctr Epidemiol, Madrid, Spain
Inst Hlth CArlos III, CIBER Enfermedades Infecciosas, Madrid, Spain
Inst Hlth Carlos II Monforte Lemos, Natl Ctr Epidemiol, Madrid 528029, Spain
Suarez-Garcia, I:
Inst Hlth CArlos III, CIBER Enfermedades Infecciosas, Madrid, Spain
Hosp Univ Infanta Sofia, Dept Internal Med, Infect Dis Unit, Madrid, Spain
Univ Europea Madrid, Fac Ciencias Biomed, Madrid, Spain
|